1stOncology™: Cancer Intelligence Service – Page 96 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development

On July 23, 2026 IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, reported that new data on IMNN-001, the Company’s DNA-based interleukin-12 (IL-12) immunotherapy for advanced ovarian cancer, will be featured in a poster presentation at the inaugural AACR (Free AACR Whitepaper) Conference on Drug Discovery and Development (AACR D3), July 21-24, 2026 in Boston, Massachusetts.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

AACR D3 is a new conference from the American Association for Cancer Research (AACR) (Free AACR Whitepaper) designed to bring together scientists, clinicians, biopharma companies and investors around emerging technologies and novel approaches spanning the drug discovery and development continuum, rather than focusing solely on late-stage clinical results. IMUNON’s presentation introduces its TheraPlas platform technology alongside supporting translational and clinical data from its ovarian cancer program.

The standard-of-care treatment for newly diagnosed advanced ovarian cancer has not meaningfully changed in three decades. IMNN-001 is a proprietary novel DNA-based agent that produces therapeutic levels of interleukin-12 (IL-12), a multipotent anti-tumor cytokine, directly to the tumor site. Unlike systemic administration of recombinant IL-12, which is associated with supraphysiological, transient exposure, IMUNON’s approach is designed to achieve durable, physiologically relevant local IL-12 production intended to drive sustained anti-tumor immune activity. Administered weekly over a 6-month period, we believe this offers a highly favorable safety and efficacy profile and has the potential to substantially improve therapeutic outcomes.

"Being selected to present at the inaugural AACR (Free AACR Whitepaper) D3 meeting is an important recognition of IMUNON’s platform and our team’s work in ovarian cancer," said Stacy Lindborg, Ph.D., president and chief executive officer of IMUNON. "The medical and scientific communities’ interest in our IMNN-001 program in advanced ovarian cancer has been remarkable. This visibility comes at a pivotal time as we advance our Phase 3 OVATION-3 trial, and we look forward to sharing our progress with this influential audience of drug developers and investors."

"We are very pleased to have been invited to present our innovative and transformative drug delivery platform, our novel translational data and the strong clinical efficacy demonstrated in our ongoing trials in ovarian cancer at this global conference," said Douglas V. Faller, M.D., Ph.D., Imunon’s chief medical officer. "The AACR (Free AACR Whitepaper) D3 meeting is the first of its kind, featuring cutting-edge science, novel technologies, and emerging frameworks that promise to revolutionize how cancer therapies are discovered, developed, and delivered. Imunon’s proven ability to safely harness, for the first time, the multipotent anti-tumor activity of IL-12 for the benefit of women with advanced ovarian cancer is being showcased as an example of the future of immune-oncology, establishing a new paradigm for immunotherapy."

Data being presented include findings from the randomized, controlled Phase 2 OVATION-2 study in advanced ovarian cancer, demonstrating that IMNN-001 is safe, achieves local delivery of IL-12, and induces anti-tumoral immune responses. The poster reports that IMNN-001 plus neoadjuvant/adjuvant chemotherapy was associated with a numerical increase in median overall survival of over 13 months compared to chemotherapy alone (40.5 vs. 27.6 months), to remain consistent with the abstract submission. As recently announced, final results from the trial increased to a 14.7 month increase in medial overall survival (45.1 vs. 30.4 months).

Translational analyses further showed that IMNN-001 enhanced favorable ratios of CD8+/Tregs and CD8+/CD4+ cells in patients’ tumors and tumor microenvironment, both of which have been previously reported to be associated with improved patient outcomes and are consistent with the clinical benefit observed in the trial. IMNN-001 was safe and well-tolerated, with no cytokine release syndrome or higher incidence of immune-related events observed in the experimental arm of OVATION-2.

These findings support the rapidly recruiting pivotal Phase 3 OVATION-3 trial, which is designed to confirm the safety and survival benefit of IMNN-001 in frontline advanced ovarian cancer; and if successful, will provide an immediate basis for a BLA filing and approval.

About IMNN-001 Immunotherapy

Designed using IMUNON’s proprietary TheraPlas platform technology, IMNN-001 is an IL-12 DNA plasmid encased in a nanoparticle delivery system that enables cell transfection followed by persistent, local production of the IL-12 protein. IL-12 is one of the most active cytokines for the induction of potent anticancer immunity acting through the induction of T-lymphocyte and natural killer cell proliferation. IMUNON previously reported positive safety and encouraging Phase 1 results with IMNN-001 administered as monotherapy or as combination therapy in patients with advanced peritoneally metastasized primary or recurrent ovarian cancer and completed a Phase 1b dose-escalation trial (the OVATION 1 Study) of IMNN-001 in combination with carboplatin and paclitaxel neoadjuvantly in patients with newly diagnosed ovarian cancer. IMUNON previously reported positive results from the recently completed Phase 2 OVATION 2 Study, which assessed IMNN-001 (100 mg/m2 administered intraperitoneally weekly) plus neoadjuvant and adjuvant chemotherapy (N/ACT) of paclitaxel and carboplatin compared to standard-of-care N/ACT alone in 112 patients with newly diagnosed advanced ovarian cancer.

(Press release, IMUNON, JUL 23, 2026, View Source [SID1234669409])

Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference

On July 23, 2026 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, reported that Sonia Quaratino, EVP Chief Medical Officer of Innate Pharma, will participate in the panel discussion, Changing Treatment Landscape in Bladder Cancer, at the BTIG Virtual Biotechnology Conference.

BTIG Virtual Biotechnology Conference 2026

Panel discussion: Changing Treatment Landscape in Bladder Cancer
Date and time: July 28, 2026, 10:30 a.m. EDT / 4:30 p.m. CEST

(Press release, Innate Pharma, JUL 23, 2026, View Source [SID1234669408])

Novocure Reports Second Quarter 2026 Financial Results

On July 23, 2026 Novocure (NASDAQ: NVCR) reported financial results for the second quarter that ended June 30, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields).

"This was our strongest quarter to date, with record net revenues and active patients on therapy," said Frank Leonard, CEO, Novocure. "We continue to launch our therapies in multiple markets allowing us to bring TTFields therapy to many more patients who can benefit. We are well-positioned to advance our patient-forward mission while driving sustainable growth and making material progress on our path to profitability."

Financial updates for the quarter ended June 30, 2026:

Total net revenues for the quarter were $183.6 million, an increase of 16% compared to the same period in 2025. This increase was primarily driven by active patient growth globally.
The U.S., Germany, France and Japan contributed $103.0 million, $23.3 million, $21.3 million and $11.8 million, respectively, with other active markets contributing $18.2 million.
$2.8 million in net revenue recognized from one-time benefits in the U.S., Germany and France.
Net revenue from Optune Lua and Optune Pax in the quarter was $7.0 million.
Recognized revenue from Optune Lua in the quarter was $5.4 million. The U.S., Germany and Japan contributed $1.9 million, $1.7 million and $1.8 million, respectively.
Recognized revenue from Optune Pax in the quarter was $1.6 million.
Revenue in Greater China from Novocure’s partnership with Zai Lab totaled $6.0 million.
Gross margin for the quarter was 78% compared to 74% in the prior year. Cost of revenues in the quarter benefitted from a one-time $4.9 million tariff refund.
Research, development and clinical study expenses for the quarter were $51.4 million, a decrease of 8% from the same period in 2025. This decrease was primarily driven by lower direct clinical trial expenses from completed trials.
Sales and marketing expenses for the quarter were $61.7 million, an increase of 8% compared to the same period in 2025. This increase was primarily driven by costs associated with the launch of Optune Pax in the U.S. and Optune Lua in Japan.
General and administrative expenses for the quarter were $39.9 million, a decrease of 9% compared to the same period in 2025. This decrease was primarily driven by lower share-based compensation expenses.
Net loss for the quarter was $15.7 million with loss per share of $0.13.
Adjusted EBITDA* for the quarter was $10.8 million.
Cash, cash equivalents and short-term investments were $440.6 million as of June 30, 2026.
Operational updates for the quarter ended June 30, 2026:

As of June 30, 2026, there were 5,128 total active patients on TTFields therapy globally.
Optune Gio
As of June 30, 2026, there were 4,636 active patients on Optune Gio, an increase of 11% from the same period in 2025.
The U.S., Germany, France and Japan contributed 2,341; 637; 471 and 553 active patients, respectively, with 634 active patients contributed by other active markets.
Optune Lua
As of June 30, 2026, there were 207 active patients on Optune Lua, an increase of 51% from the same period in 2025.
The U.S., Germany, France and Japan contributed 99; 38; 1 and 64 active patients, respectively, with 5 active patients contributed by other active markets.
Optune Pax
418 prescriptions for Optune Pax were received in the quarter.
As of June 30, 2026, there were 285 active patients on Optune Pax in the U.S.
Quarterly updates and achievements:

June 2026
Optune Pax received CE (Conformité Européenne) Mark for the treatment of adult patients with locally advanced pancreatic cancer of exocrine origin, concomitant with gemcitabine and nab-paclitaxel (gem/nab-pac) in accordance with guideline recommendations.
2026 financial guidance:

Novocure’s updated guidance for the full year 2026, as of July 23, 2026, is summarized below:

Total net revenue: $710 million – $725 million (previous: $690 million – $710 million)
Guidance includes collective net revenue contribution from Optune Lua and Optune Pax between $20 million – $30 million.
Adjusted EBITDA*: $0 million – $15 million (previous: $(15) million – $0 million)
This guidance assumes full-year mid-to-high single digit net revenue growth from Optune Gio, foreign exchange rates as of June 30, 2026 and consistent quarterly gross margin in the mid-70s percent.

Anticipated clinical and regulatory milestones:

Decision by the U.S. Food and Drug Administration on the premarket approval application for use of TTFields therapy for the treatment of brain metastases from non-small cell lung cancer (Q4 2026).
Complete enrollment in Phase 3 KEYNOTE D58 clinical trial in newly diagnosed glioblastoma (Q4 2026).
Conference call details

Novocure will host a conference call and webcast to discuss second quarter 2026 financial results at 8:00 a.m. EDT today, Thursday, July 23, 2026. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link.

The webcast, earnings slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of Novocure’s website, investor.novocure.com, and will be available for at least 14 days following the call. Novocure has used, and intends to continue to use, its investor relations website, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

(Press release, NovoCure, JUL 23, 2026, View Source [SID1234669407])

Infinitopes Doses First Patient With Precision Off-the-Shelf Therapeutic Cancer Vaccine ITOP1

On July 23, 2026 Infinitopes, a clinical-stage biotechnology company developing precision, off-the-shelf therapeutic cancer vaccines for solid tumours, reported that the first patient has been dosed with ITOP1, the company’s lead investigational therapeutic cancer vaccine candidate.

This marks the first clinical evaluation of Infinitopes’ Precision Immunomics platform, which combines large-scale immunopeptidomic antigen discovery with proprietary engineered viral vector technologies, to identify naturally presented tumour antigens capable of generating durable anti-tumour T-cell responses.

The VISTA study (Vaccination with ITOP1 in resectable oesophageal adenocarcinoma to evaluate Safety, Tolerability and Anti-tumour activity) is a multicentre, randomised, double-blind, placebo-controlled Phase 1/2a clinical trial conducted in partnership with the University of Oxford. The study will evaluate ITOP1 in patients with newly diagnosed, surgically resectable oesophageal and gastro-oesophageal junction adenocarcinoma (OAC).

Unlike alternative therapeutic vaccination approaches after surgery, VISTA investigates early treatment, while the primary tumour remains in situ. This neoadjuvant approach is designed to test whether earlier immune priming, in the presence of the patient’s tumour antigens, can generate stronger anti-tumour T-cell responses alongside standard-of-care treatment.

Current standard-of-care for resectable OAC consists of neoadjuvant FLOT / durvalumab chemoimmunotherapy, surgery, and adjuvant chemoimmunotherapy. In the VISTA protocol, ITOP1 is administered between chemoimmunotherapy and surgery, both before and after oesophagectomy, allowing investigators to evaluate vaccine-induced immune responses throughout first-line treatment.

Infinitopes’ Precision Immunomics platform identifies tumour antigens naturally presented by cancer cells through direct immunopeptidomic analysis, including both canonical and non-canonical targets. These antigens are incorporated into the company’s proprietary engineered viral vector platform, designed to generate potent and durable T-cell immunity against solid tumours.

Investigators will evaluate the safety and tolerability of ITOP1 together with vaccine-induced immune responses and exploratory biomarkers associated with anti-tumour activity and disease recurrence.

Professor Mark Middleton

Chief Investigator, VISTA Trial; Head of the Department of Oncology, University of Oxford; Consultant Medical Oncologist, Oxford University Hospitals NHS Foundation Trust

"The first patient dosed in VISTA is an important landmark for our programme and for the wider field of therapeutic cancer vaccines. The neoadjuvant setting provides a fantastic opportunity to study immune responses while the patient’s primary tumour is still there. VISTA is designed to determine if this approach safely generates meaningful anti-tumour immunity and can delay recurrence after standard treatment and surgery."

Dr Jonathan Kwok
Co-Founder, President and Chief Medical Officer, Infinitopes

"Entering the clinic is a defining milestone for successful future medicines. For Infinitopes, VISTA represents the first clinical evaluation of our integrated approach that combines Precision Immunomics target discovery with proven viral vectors, to engineer precise, off-the-shelf therapies for cancer patients.

"By identifying the antigens that are naturally presented by patients’ tumours, and delivering these using vectors designed to generate durable T-cell immunity, we believe this approach has the potential to build an exciting pipeline of future programmes across multiple solid tumours. We look forward to evaluating the safety and immunological signals from early 2027."

The Phase 1 safety lead-in will recruit eight participants, to evaluate safety, tolerability and vaccine-induced immunity, before continuing into the randomised, placebo-controlled Phase 2a stage enrolling an additional 52 participants.

Initial safety and immunological data from the Phase 1 cohort are anticipated from early 2027.

The first patient dosed in VISTA marks an important milestone in Infinitopes’ evolution from an academic spinout to a clinical-stage biotechnology company. Founded through support from multiple Cancer Research UK awards and the University of Oxford, Infinitopes has built integrated capabilities spanning antigen discovery, immunology, vaccinology, vector engineering, biomanufacturing and clinical development.

Further information about the study is available through the UK Clinical Trials Registry (IRAS 1008088).

(Press release, Infinitopes, JUL 23, 2026, View Source [SID1234669406])

Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

On July 23, 2026 Agilent Technologies Inc. (NYSE: A) reported it has received European Union (EU) certification for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA (pembrolizumab), Merck’s (known as MSD outside the United States and Canada) anti-PD-1 therapy.

PD-L1 IHC 22C3 pharmDx, Code SK006, enables pathologists to assess PD-L1 expression to identify patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who may be eligible for treatment with pembrolizumab, in accordance with the approved product labelling, supporting informed treatment decisions in a disease where therapeutic options remain limited for many patients. This approval marks the eighth CE-marked companion diagnostic indication currently available for PD-L1 IHC 22C3 pharmDx, Code SK006 in the EU.

"Expanding access to precision oncology across regions is essential to improving patient outcomes," said Majken Nielsen, vice president and general manager of Agilent’s Clinical Diagnostics Division. "This EU approval builds on our commitment to deliver high-quality companion diagnostics and enables laboratories to support more informed treatment decisions for patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma."

PD-L1 expression in epithelial ovarian, fallopian tube, or primary peritoneal carcinoma was evaluated using PD-L1 IHC 22C3 pharmDx, Code SK006, in the KEYNOTE-B96/ENGOT -ov65 clinical trial, supporting its use as an aid in identifying patients who may be eligible for treatment with pembrolizumab in the platinum-resistant setting.

In addition, PD-L1 IHC 22C3 pharmDx, Code SK006, is indicated in the EU to help physicians identify patients across several tumor types, including non-small cell lung cancer (NSCLC), esophageal cancer, cervical cancer, head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), gastric or gastroesophageal junction (GEJ) adenocarcinoma and urothelial carcinoma, who may be eligible for treatment with KEYTRUDA, in accordance with the approved product labelling.

PD-L1 IHC 22C3 pharmDx, Code SK006, was developed by Agilent in partnership with Merck (known as MSD outside of the United States and Canada) as a companion diagnostic for KEYTRUDA.

KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA

See the KEYTRUDA product label for specific clinical circumstances guiding therapy

(Press release, Agilent, JUL 23, 2026, View Source [SID1234669405])